Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Pieternella J Lugtenburg, MD PhD, Josée M Zijlstra, MD, Jeanette K Doorduijn, MD PhD, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD PhD, Mels Hoogendoorn, MD PhD, Henriette W Berenschot, MD, Aart Beeker, MD, Fransje Valster, MD, Harry C. Schouten, MD PhD, Marleen Luten, MSc, Henk Hofwegen, Dana A Chitu, PhD, Rolf E Brouwer, MD PhD, Gustaaf W van Imhoff, MD PhD

Blood (2015) 126 (23): 2707.

https://doi.org/10.1182/blood.V126.23.2707.2707

Published: 2015

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Pier Luigi Zinzani, Bertrand Coiffier, MD PhD, John Radford, Dolores Caballero, Paul Fields, MD PhD, Martine ED Chamuleau, MD, Francesco d'Amore, Corinne Haioun, MD PhD, Catherine Thieblemont, MD PhD, Eva González Barca, MD PhD, Carlos Grande García, MD, Peter W Johnson, MD, Gustaaf W van Imhoff, MD PhD, Andrew Saunders, MD, Karen Dwyer, Franck Morschhauser, MD PhD

Blood (2014) 124 (21): 1763.

https://doi.org/10.1182/blood.V124.21.1763.1763

Published: 2014

Journal Articles

Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma.

Zheng Liang, MD, Arjan Diepstra, MD PhD, Chuanhui Xu, MD PhD, Gustaaf W van Imhoff, MD, PhD, Wouter J Plattel, MD, Anke Van Den Berg, PhD, Lydia Visser, PhD

Blood (2012) 120 (21): 2640.

https://doi.org/10.1182/blood.V120.21.2640.2640

Published: 2012

Journal Articles

Treatment of Secondary Central Nervous System Lymphoma with Intrathecal Rituximab, High Dose Methotrexate and R-DHAP, Followed by Autologous Stem Cell Transplantation. A Phase II HOVON Study

Jeanette K Doorduyn, MD, PhD, Gustaaf W van Imhoff, MD, PhD, Kees CAGM van Montfort, PhD, Harry C Schouten, MD, PhD, Martyn Ronald Schaafsma, Johanna W. Baars, MD, PhD, Marie Jose Kersten, MD, PhD, Elly Lugtenburg, MD, PhD, Martin M.J. van den Bent, MD, PhD, Roelien Enting, Philip M.P. Poortmans, MD, PhD, Jacoline J.E.C. Bromberg, MD, PhD

Blood (2012) 120 (21): 306.

https://doi.org/10.1182/blood.V120.21.306.306

Published: 2012

Journal Articles

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Pieternella J Lugtenburg, MD, PhD, Josée M Zijlstra, MD, PhD, Jeanette K Doorduijn, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD, PhD, Mels Hoogendoorn, MD, PhD, Henriette W Berenschot, MD, PhD, Aart Beeker, MD, Fransje A Valster, MD, Harry C Schouten, MD, PhD, Marleen Luten, MSc, Dana A Chitu, Rolf E Brouwer, MD, PhD, Gustaaf W van Imhoff, MD, PhD

Blood (2012) 120 (21): 2729.

https://doi.org/10.1182/blood.V120.21.2729.2729

Published: 2012

Journal Articles

Double-hit B-cell lymphomas

Sietse M. Aukema, Reiner Siebert, Ed Schuuring, Gustaaf W. van Imhoff, Hanneke C. Kluin-Nelemans, Evert-Jan Boerma, Philip M. Kluin

Blood (2011) 117 (8): 2319–2331.

https://doi.org/10.1182/blood-2010-09-297879

Published: 2011

Includes: Supplemental data

Journal Articles

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.

J.C. Kluin-Nelemans, MD, PhD, Marinus Van Marwijk Kooij, MD, PhD, P.J. Lugtenburg, MD, PhD, Pierre W Wijermans, Willem JL Van Putten, MSc, Gustaaf W van Imhoff, MD, PhD

Blood (2008) 112 (11): 1999.

https://doi.org/10.1182/blood.V112.11.1999.1999

Published: 2008

Journal Articles

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma

Hanneke C. Kluin-Nelemans, Jules L. Coenen, James E. Boers, Gustaaf W. van Imhoff, Stefano Rosati

Blood (2008) 112 (4): 1039–1041.

https://doi.org/10.1182/blood-2008-02-138800

Published: 2008

Journal Articles

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial

Edo Vellenga, Wim L. J. van Putten, Mars B. van 't Veer, Josée M. Zijlstra, Willem E. Fibbe, Marinus H. J. van Oers, Leo F. Verdonck, Pierre W. Wijermans, Gustaaf W. van Imhoff, Pieternella J. Lugtenburg, Peter C. Huijgens

Blood (2008) 111 (2): 537–543.

https://doi.org/10.1182/blood-2007-08-108415

Published: 2008

Includes: Supplemental data

Journal Articles

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

Leo F. Verdonck, Annelise Notenboom, Daphne D. de Jong, Marius A. MacKenzie, Gregor E. G. Verhoef, Mark H. H. Kramer, Gert J. Ossenkoppele, Jeanette K. Doorduijn, Pieter Sonneveld, Gustaaf W. van Imhoff

Blood (2006) 109 (7): 2759–2766.

https://doi.org/10.1182/blood-2006-07-035709

Published: 2006

Includes: Supplemental data

Journal Articles

Rituximab (Mabthera) Improves the Treatment Results of DHAP-VIM-DHAP and ASCT in Relapsed/Progressive Aggressive CD20 + NHL. A Prospective Randomized HOVON Trial.

Edo Vellenga, MD, PhD, Annelise Notenboom, PhD, Mars van ‘t Veer, MDPhD, Josée Zijlstra, MD, Willem E. Fibbe, MDPhD, Rien van Oers, MDPhD, Gustaaf W. van Imhoff, MDPhD, Elly Lugtenburg, MDPhD, P.C. Huijgens, MDPhD

Blood (2006) 108 (11): 328.

https://doi.org/10.1182/blood.V108.11.328.328

Published: 2006

Journal Articles

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Pieter Sonneveld, MD, Wim van Putten, MsC, Douwe Biesma, MD, Harald Holte, MD, Marinus van Marwijk Kooij, MD, Mark Henri H. Kramer, MD, P.W. Wijermans, MD, Monique Steijaert, Gustaaf W. van Imhoff, MD, P.J. Lugtenburg, MD, P.C. Huijgens, MD, Mikael Eriksson, MD

Blood (2006) 108 (11): 210.

https://doi.org/10.1182/blood.V108.11.210.210

Published: 2006

Journal Articles

Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.

Bart W. Schot, MD, Josée Zijlstra, MD, Otto S. Hoekstra, MDPhD, Jan Pruim, MDPhD, Gustaaf W. van Imhoff, MD, Wim Sluiter, PhD, John M.M. Raemaekers, MDPhD, Wim Oyen, MDPhD, Michel Van Gelder, MDPhD, Olga Eriks, PhD, P.C. Huijgens, MDPhD, Edo Vellenga, MDPhD

Blood (2006) 108 (11): 2400.

https://doi.org/10.1182/blood.V108.11.2400.2400

Published: 2006

Journal Articles

Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma

Bart W. Schot, Josée M. Zijlstra, Wim J. Sluiter, Gustaaf W. van Imhoff, Jan Pruim, Willem Vaalburg, Edo Vellenga

Blood (2006) 109 (2): 486–491.

https://doi.org/10.1182/blood-2005-11-006957

Published: 2006

Journal Articles

Six Courses of Intensified CHOP Plus G-CSF Compared to Eight Courses of Standard CHOP in Patients with Intermediate-Risk Aggressive Non-Hodgkin Lymphoma Results of a Prospective Randomized HOVON Trial.

Leo F. Verdonck, MD, PhD, Gustaaf W. van Imhoff, MD, John M.M. Raemakers, MD, PhD, Gregor Verhoef, MD, PhD, Mark H.H. Kramer, MD, PhD, Gert J. Ossenkoppele, MD, PhD, Jeanette K. Doorduijn, MD, PhD, Ine A.M.H. Meulendijks, MD, PhD, Wessel N. van Wieringen, MD, PhD, Pieter Sonneveld, MD, PhD

Blood (2005) 106 (11): 14.

https://doi.org/10.1182/blood.V106.11.14.14

Published: 2005

Journal Articles

All IPI Factors Are Equal, but LDH Is More Equal Than Others.

Gustaaf W. van Imhoff, MD, W. Graveland, B. Van der Holt, M. Van Glabbeke, PhD, L. F. Verdonck, MD, PhD, P. Sonneveld, MD, PhD, J. C. Kluin-Nelemans, MD, PhD

Blood (2005) 106 (11): 1913.

https://doi.org/10.1182/blood.V106.11.1913.1913

Published: 2005

Journal Articles

PTLD Visualization by FDG-PET: Improved Detection of Extranodal Localizations and Response Monitoring.

Nicolaas A. Bakker, MSc, Jan Pruim, MD, PhD, Willem J. Van Son, MD, PhD, Eric J. Van der Jagt, MD, PhD, Hanneke C. Kluin-Nelemans, MD, PhD, Gustaaf W. Van Imhoff, MD

Blood (2005) 106 (11): 5389.

https://doi.org/10.1182/blood.V106.11.5389.5389

Published: 2005

Journal Articles

Outcome of Patients > Age 40 with Burkitt Lymphoma (BL) Treated with Aggressive Chemotherapuetic Regimens: Results from the International Burkitt Lymphoma Collaborative Group.

Jonathan W. Friedberg, MD, Lauren Ciminello, Jennifer Kelly, Simon Clawson, MD, Dieter Hoelzer, MD, Harald Holte, MD, Ann S. LaCasce, MD, Graham Mead, MD, Deborah Thomas, MD, Gustaaf W. van Imhoff, MD, Bruce Cheson, MD, Ian T. Magrath, MB, Richard I. Fisher, MD

Blood (2005) 106 (11): 928.

https://doi.org/10.1182/blood.V106.11.928.928

Published: 2005

Journal Articles

Population Based Genotyping of Human Leukocyte Antigen (HLA) in Hodgkin Lymphoma: EBV Positive HL Is Associated with HLA Class I and EBV Negative HL Is Associated with HLA Class III.

Arjan Diepstra, MD, Marijke Niens, MSc, Edo Vellenga, MD, PhD, Gerard J. te Meerman, PhD, Michael Schaapveld, PhD, Ilja M. Nolte, PhD, Gustaaf W. van Imhoff, MD, Sibrand Poppema, MD, PhD

Blood (2004) 104 (11): 432.

https://doi.org/10.1182/blood.V104.11.432.432

Published: 2004

NARROW

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma.

Treatment of Secondary Central Nervous System Lymphoma with Intrathecal Rituximab, High Dose Methotrexate and R-DHAP, Followed by Autologous Stem Cell Transplantation. A Phase II HOVON Study

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Double-hit B-cell lymphomas

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

Rituximab (Mabthera) Improves the Treatment Results of DHAP-VIM-DHAP and ASCT in Relapsed/Progressive Aggressive CD20 + NHL. A Prospective Randomized HOVON Trial.

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.

Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma

Six Courses of Intensified CHOP Plus G-CSF Compared to Eight Courses of Standard CHOP in Patients with Intermediate-Risk Aggressive Non-Hodgkin Lymphoma Results of a Prospective Randomized HOVON Trial.

All IPI Factors Are Equal, but LDH Is More Equal Than Others.

PTLD Visualization by FDG-PET: Improved Detection of Extranodal Localizations and Response Monitoring.

Outcome of Patients > Age 40 with Burkitt Lymphoma (BL) Treated with Aggressive Chemotherapuetic Regimens: Results from the International Burkitt Lymphoma Collaborative Group.

Population Based Genotyping of Human Leukocyte Antigen (HLA) in Hodgkin Lymphoma: EBV Positive HL Is Associated with HLA Class I and EBV Negative HL Is Associated with HLA Class III.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only